Pre-existing evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review.
Auteurs : Bregni G, Trevisi E, Saude Conde R, Vanhooren M, Akin Telli T, Assaf I, Hendlisz A, Di Maio M, Sclafani F Jaar : 2023 Journal : J Natl Cancer Inst
Mind the target: human epidermal growth factor receptor 2 in colorectal cancer.
Auteurs : Saude Conde R, Rasschaert G, Bregni G, Hendlisz A, Sclafani F Jaar : 2022 Journal : Curr Opin Oncol
Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.
Auteurs : Akin Telli T, Bregni G, Vanhooren M, Saude Conde R, Hendlisz A, Sclafani F Jaar : 2022 Journal : Cancer Treat Rev
JCOG0603: Are We Really Sure This Was a Negative Trial?
Auteurs : Saude Conde R, Bregni G, Saad E, Hendlisz A, Sclafani F Jaar : 2022 Journal : J Clin Oncol
The Exciting New Field of HER2-Low Breast Cancer Treatment.
Auteurs : Eiger D, Agostinetto E, Saude Conde R, de Azambuja E Jaar : 2021 Journal : Cancers (Basel)